AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8689423 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD AraC) 2 x 10 mg/m2 sc, day 1-14 plus interleukin-3 (IL-3) once daily sc, day 8-21 at varying doses (1.0, 2.5, 5.0, and 10.0 micrograms/kg)
Number of subjects: 31
Study 1364935 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated naproxen (Nycopren)
Number of subjects: 348
Study 1364935 — intervention group
Group type: COMPARATOR
Intervention: Standard naproxen
Number of subjects: 348
Study 31856049 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy
Number of subjects: 0
Study 31856049 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (placebo group)
Number of subjects: 0
Study 29137628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) pre-injection 4 mL/kg 7.5% HS
Number of subjects: 120
Study 29137628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) pre-injection
Number of subjects: 120
Study 29137628 — intervention group
Group type: COMPARATOR
Intervention: Control group (NS group) pre-injection 4 mL/kg isotonic saline
Number of subjects: 120
Study 26637580 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-dose azithromycin (250 mg daily for 3 months) plus standard conventional treatment (fluticasone nasal spray plus normal saline solution irrigation)
Number of subjects: 66
Study 26637580 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional treatment (fluticasone nasal spray plus normal saline solution irrigation)
Number of subjects: 66
Study 24924416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (500 mg IM days 1, 15, 29, then monthly) plus Vandetanib (100 mg PO OD)
Number of subjects: 127
Study 24924416 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant (500 mg IM days 1, 15, 29, then monthly) plus Placebo
Number of subjects: 127
Study 24924416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Vandetanib
Number of subjects: 127
Study 24924416 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus Placebo
Number of subjects: 127
Study 24924416 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline uNTx (>65 nM BCE/mmol Cr)
Number of subjects: 127
Study 23767201 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 0
Study 23767201 — intervention group
Group type: COMPARATOR
Intervention: Citicoline
Number of subjects: 0
Study 23767201 — intervention group
Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 0
Study 19463034 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy (10-week project with ten one-hour weekly sessions including song singing, song writing, and improvisation)
Number of subjects: 0
Study 19463034 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy
Number of subjects: 0
Study 18628615 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin bridging
Number of subjects: 376
Study 18628615 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 376
Study 16131696 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg caffeine . kg(‐1) . d(‐1) (C3)
Number of subjects: 59
Study 16131696 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg caffeine . kg(‐1) . d(‐1) (C6)
Number of subjects: 59
Study 16131696 — intervention group
Group type: COMPARATOR
Intervention: 0 mg caffeine . kg(‐1) . d(‐1) (C0; placebo)
Number of subjects: 59
Study 12354682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition information about energy density of meals
Number of subjects: 40
Study 12354682 — intervention group
Group type: COMPARATOR
Intervention: No nutrition information
Number of subjects: 40
Study 9987086 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) 0.6 g.kg-1.24 hr-1, N = 14
Number of subjects: 29
Study 9987086 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (NPD), N = 15
Number of subjects: 29
Study 9987086 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) during phase II
Number of subjects: 29
Study 9987086 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (NPD) during phase II
Number of subjects: 29
Study 9987086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 7591421 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon plates with added vitamin E
Number of subjects: 80
Study 7591421 — intervention group
Group type: COMPARATOR
Intervention: Simple silicone gel sheets
Number of subjects: 80
Study 1967730 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit killed whole‐cell (BS‐WC)
Number of subjects: 62285
Study 1967730 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole‐cell (WC)
Number of subjects: 62285
Study 7427409 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg daily for three weeks) with Propranolol
Number of subjects: 15
Study 7427409 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg daily for three weeks) with Thiazide diuretics
Number of subjects: 15
Study 7427409 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Propranolol
Number of subjects: 15
Study 7427409 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Thiazide diuretics
Number of subjects: 15
Study 30803290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative plus postoperative hemoadsorption therapy
Number of subjects: 20
Study 30803290 — intervention group
Group type: COMPARATOR
Intervention: Sole intraoperative hemoadsorption therapy
Number of subjects: 20
Study 29280118 — intervention group
Group type: EXPERIMENTAL
Intervention: Microecological treatment group
Number of subjects: 198
Study 29280118 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 198
Study 29280118 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 198
Study 25902320 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 ng•mL with propofol TCI between 2.40 and 4.23 μg•mL (bolus of 1 mg•kg)
Number of subjects: 124
Study 25902320 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 ng•mL with propofol TCI between 2.15 and 2.88 μg•mL (bolus of 0.75 mg•kg)
Number of subjects: 124
Study 25902320 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol fixed at 2 μg•mL with remifentanil TCI between 1.00 to 4.79 ng•mL
Number of subjects: 124
Study 25902320 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol fixed at 3 μg•mL with remifentanil TCI between 0.72 to 3.19 ng•mL
Number of subjects: 124
Study 24079288 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole eggs (EGG, n = 20)
Number of subjects: 37
Study 24079288 — intervention group
Group type: COMPARATOR
Intervention: Egg substitute (SUB, n = 17)
Number of subjects: 37
Study 24079288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EGG and SUB)
Number of subjects: 37
Study 21131862 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third maintenance dose of resistance training
Number of subjects: 70
Study 21131862 — intervention group
Group type: EXPERIMENTAL
Intervention: One-ninth maintenance dose of resistance training
Number of subjects: 70
Study 21131862 — intervention group
Group type: COMPARATOR
Intervention: Detraining
Number of subjects: 70
Study 21131862 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength gained during phase 1
Number of subjects: 70
Study 19750261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1.5 g/day, 500 mg every 8 hours)
Number of subjects: 60
Study 19750261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17520360 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to breathing instructions
Number of subjects: 43
Study 17520360 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow breathing instructions
Number of subjects: 43
Study 17520360 — intervention group
Group type: COMPARATOR
Intervention: Anti-hyperventilation instructions
Number of subjects: 43
Study 17520360 — intervention group
Group type: COMPARATOR
Intervention: Heart rate and skin conductance measures
Number of subjects: 43
Study 14687740 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual removal of the placenta (n=100)
Number of subjects: 200
Study 14687740 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous separation of the placenta (n=100)
Number of subjects: 200
Study 11348713 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosomal vaccine
Number of subjects: 285
Study 11348713 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 285
Study 11348713 — intervention group
Group type: EXPERIMENTAL
Intervention: Split vaccine
Number of subjects: 285
Study 11348713 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 285
Study 9404473 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam
Number of subjects: 258
Study 9404473 — intervention group
Group type: COMPARATOR
Intervention: 100 mg diclofenac
Number of subjects: 258
Study 8265329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation from pregnancy through second year of the child's life
Number of subjects: 400
Study 2889397 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30
Study 2889397 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 30
Study 29476542 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient treatment (specific emollients not detailed)
Number of subjects: 197
Study 26836747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel titanium (NiTi) springs
Number of subjects: 40
Study 26836747 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel (SS) springs
Number of subjects: 40
Study 26836747 — intervention group
Group type: COMPARATOR
Intervention: Comparison of NiTi and SS springs
Number of subjects: 40
Study 25431023 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Rhythm Control (ARC)
Number of subjects: 52
Study 25431023 — intervention group
Group type: COMPARATOR
Intervention: AF
Number of subjects: 52
Study 23584615 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic play (TP) during EBRT
Number of subjects: 19
Study 23584615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic play)
Number of subjects: 19
Study 20381164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 0
Study 20381164 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 0
Study 19029501 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist and nurse care intervention including BP wallet card, cardiovascular risk reduction education, hypertension education pamphlet, referral to primary care physician, evidence summary for physician, and 4 follow-up visits over 6 months.
Number of subjects: 227
Study 19029501 — intervention group
Group type: COMPARATOR
Intervention: Control group received a BP wallet card, pamphlet on diabetes, general diabetes advice, and usual care by their physician.
Number of subjects: 227
Study 19029501 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist and nurse care intervention for patients with baseline systolic BP greater than 160 mm Hg.
Number of subjects: 227
Study 16608936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) for 16 weeks including breathing retraining and exercise
Number of subjects: 40
Study 12055813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (100 mg for age 1-3 years or 200 mg for age 4-11 years, twice daily for 3 days)
Number of subjects: 85
Study 12055813 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg single dose)
Number of subjects: 85
Study 12055813 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (25 mg/kg single dose)
Number of subjects: 85
Study 10480704 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fasting serum true insulin concentration
Number of subjects: 5550
Study 10480704 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fasting serum glucose > or =6.1 mmol/l at baseline
Number of subjects: 5550
Study 8983443 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer level detected using semiquantitative method (D‐dimer Latex Test, Diagnostica Stago‐Boehringer Mannheim) before and during treatment.
Number of subjects: 33
Study 8983443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cells number and composition using light microscope before and during treatment.
Number of subjects: 33
Study 8983443 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer level in tuberculous effusions before treatment.
Number of subjects: 33
Study 8983443 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer level in neoplastic pleural effusion.
Number of subjects: 33
Study 8983443 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer level in blood.
Number of subjects: 33
Study 1765040 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose fentanyl (20 micrograms kg-1) combined with isoflurane, nitrous oxide and oxygen
Number of subjects: 20
Study 1765040 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracolumbar epidural bupivacaine combined with isoflurane, nitrous oxide and oxygen
Number of subjects: 20
Study 6604371 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodymium-Yag laser treatment
Number of subjects: 130
Study 6604371 — intervention group
Group type: EXPERIMENTAL
Intervention: Yag laser photocoagulation
Number of subjects: 130
Study 29274892 — intervention group
Group type: EXPERIMENTAL
Intervention: 45g/day of resistant starch (RS=amylose) for 12 weeks
Number of subjects: 68
Study 29274892 — intervention group
Group type: COMPARATOR
Intervention: Amylopectin (Control) for 12 weeks
Number of subjects: 68
Study 27174694 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 30 U/kg
Number of subjects: 23
Study 27174694 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 60 U/kg
Number of subjects: 23
Study 24496072 — intervention group
Group type: EXPERIMENTAL
Intervention: CACE‐Is (n = 91)
Number of subjects: 406
Study 24496072 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (part of CACE‐Is)
Number of subjects: 406
Study 24496072 — intervention group
Group type: COMPARATOR
Intervention: NoCACE‐I (n = 274)
Number of subjects: 406
Study 22769569 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT adjuvant therapy (500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by 2-day rest, repeated for 1 year)
Number of subjects: 2024
Study 22769569 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT adjuvant therapy
Number of subjects: 2024
Study 22769569 — intervention group
Group type: COMPARATOR
Intervention: Observation without any adjuvant treatment
Number of subjects: 2024
Study 20484482 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 19
Study 18824368 — intervention group
Group type: EXPERIMENTAL
Intervention: MCABG
Number of subjects: 30
Study 18824368 — intervention group
Group type: COMPARATOR
Intervention: CCABG
Number of subjects: 30
Study 18824368 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 30
Study 15933481 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (25, 50 or 75 mg every 2 weeks)
Number of subjects: 439
Study 15933481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 15933481 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone
Number of subjects: 439
Study 15933481 — intervention group
Group type: COMPARATOR
Intervention: Long-acting risperidone and Placebo
Number of subjects: 439
Study 12646338 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 615
Study 10771799 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifier (HH)
Number of subjects: 0
Study 10771799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic heat and moisture exchanger (HHME)
Number of subjects: 0
Study 10771799 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 0
Study 8783991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (full recommended dose) in group D
Number of subjects: 70
Study 8783991 — intervention group
Group type: COMPARATOR
Intervention: No aprotinin in group C
Number of subjects: 70
Study 1474275 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 0.1 mg + 6 x 10(8) KML (I)
Number of subjects: 997
Study 1474275 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 0.1 mg + 5 x 10(7) KML (II)
Number of subjects: 997
Study 1474275 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 0.1 mg + 5 x 10(6) KML (III)
Number of subjects: 997
Study 1474275 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 0.1 mg (IV)
Number of subjects: 997
Study 1474275 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (V)
Number of subjects: 997
Study 6204413 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (10 ng/kg/min before CPB and 50 ng/kg/min during CPB)
Number of subjects: 20
Study 6204413 — intervention group
Group type: COMPARATOR
Intervention: Control (3 mg/kg heparin)
Number of subjects: 20
Study 6204413 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion before CPB
Number of subjects: 20
Study 31228612 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation at disease-affected finger joint (P50)
Number of subjects: 31
Study 31228612 — intervention group
Group type: COMPARATOR
Intervention: Painful stimulation at non-affected thumbnail (P50)
Number of subjects: 31
Study 31228612 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation at disease-affected joint
Number of subjects: 31
Study 31228612 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation at disease-affected joints
Number of subjects: 31
Study 30325656 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed 640G system with continuous glucose monitoring (CGM) and SmartGuard PLGM feature for 24 weeks
Number of subjects: 0
Study 30325656 — intervention group
Group type: COMPARATOR
Intervention: MiniMed 640G without CGM and with blinded continuous glucose measurements
Number of subjects: 0
Study 26581889 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge with ETEC strain H10407
Number of subjects: 0
Study 26581889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge with ETEC strain H10407
Number of subjects: 0
Study 26581889 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial challenge with ETEC strain H10407
Number of subjects: 0
Study 24825343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dialysis heparin coating of the membrane
Number of subjects: 46
Study 24825343 — intervention group
Group type: COMPARATOR
Intervention: Intermittent saline flushes
Number of subjects: 46
Study 24825343 — intervention group
Group type: COMPARATOR
Intervention: Constant saline infusion
Number of subjects: 46
Study 21954198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (videobooklet)
Number of subjects: 208
Study 21954198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (videobooklet) + adaptive conjoint analysis (ACA) tool
Number of subjects: 208
Study 21954198 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet on OA management (control)
Number of subjects: 208
Study 21105281 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone at 6 mg/d plus buspirone at 60 mg/d
Number of subjects: 46
Study 21105281 — intervention group
Group type: COMPARATOR
Intervention: Risperidone at 6 mg/d plus placebo
Number of subjects: 46
Study 18180629 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U of BTXA
Number of subjects: 20
Study 18180629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15818699 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 104
Study 15818699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 12842375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral opioid analgesia
Number of subjects: 37
Study 12842375 — intervention group
Group type: COMPARATOR
Intervention: Non-opioid analgesia
Number of subjects: 37
Study 12842375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 10658520 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (200 mg/m2) and cisplatin (60 mg/m2) with ifosfamide
Number of subjects: 505
Study 10658520 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (200 mg/m2) and cisplatin (60 mg/m2) without ifosfamide
Number of subjects: 505
Study 8889289 — intervention group
Group type: EXPERIMENTAL
Intervention: Enadoline 25 micrograms
Number of subjects: 0
Study 8889289 — intervention group
Group type: EXPERIMENTAL
Intervention: Enadoline 15 micrograms
Number of subjects: 0
Study 8889289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8889289 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg i.m.
Number of subjects: 0
Study 8889289 — intervention group
Group type: EXPERIMENTAL
Intervention: Enadoline (2, 5, 15 micrograms)
Number of subjects: 0
Study 8889289 — intervention group
Group type: COMPARATOR
Intervention: ACET/COD combination
Number of subjects: 0
Study 2060561 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (500-4000 micrograms)
Number of subjects: 17
Study 2060561 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (500-4000 micrograms)
Number of subjects: 17
Study 2060561 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline and Salbutamol (500-4000 micrograms)
Number of subjects: 17
Study 2060561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6209500 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg tid)
Number of subjects: 15
Study 6209500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6209500 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (after placebo)
Number of subjects: 15
Study 6209500 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (during treatment)
Number of subjects: 15
Study 31603076 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagal Nerve Stimulation (t-VNS) using GammaCore device for 2 weeks, self-administered three times per day.
Number of subjects: 21
Study 31603076 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment for 2 weeks, self-administered three times per day.
Number of subjects: 21